Menu
Search
|

Menu

Close
X

AtriCure Inc ATRC.OQ (NASDAQ Stock Exchange Global Market)

25.51 USD
+0.47 (+1.88%)
As of Sep 13
Previous Close 25.04
Open 25.05
Volume 89,471
3m Avg Volume 76,651
Today’s High 25.67
Today’s Low 24.99
52 Week High 36.08
52 Week Low 22.57
Shares Outstanding (mil) 34.33
Market Capitalization (mil) 804.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
113
FY18
202
FY17
175
FY16
155
EPS (USD)
FY19
-0.262
FY18
-0.659
FY17
-0.797
FY16
-1.055
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
4.85
7.91
Price to Book (MRQ)
vs sector
4.98
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
24.00
14.55
LT Debt to Equity (MRQ)
vs sector
20.72
10.20
Return on Investment (TTM)
vs sector
-13.17
14.48
Return on Equity (TTM)
vs sector
-19.19
15.78

EXECUTIVE LEADERSHIP

Scott Drake
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Michael Carrel
President, Chief Executive Officer, Director, Since 2012
Salary: $714,375.00
Bonus: $822,816.00
Andrew Wade
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $392,569.00
Bonus: $299,982.00
Douglas Seith
Chief Operating Officer, Since 2015
Salary: $435,998.00
Bonus: $492,561.00
Justin Noznesky
Senior Vice President, Marketing and Business Development, Since 2016
Salary: $342,109.00
Bonus: $260,355.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

7555 Innovation Way
MASON   OH   45040-9695

Phone: +1513.7554100

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

SPONSORED STORIES